GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ)

$0.5532 0.0397 (7.7313%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 87

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) News Sources

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

31-03-2026

yahoo.com

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

09-04-2026

yahoo.com

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

14-04-2026

yahoo.com

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

06-05-2026

yahoo.com

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

14-05-2026

yahoo.com

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

02-06-2026

yahoo.com

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

08-06-2026

yahoo.com

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition

22-06-2026

yahoo.com

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

16-07-2026

yahoo.com

Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)

16-07-2026

advfn.com

GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) Sentiment Trend

0 25 50 75 100 86 86 86 88 83 89 91 88 87 89 31-03-2026 09-04-2026 14-04-2026 06-05-2026 14-05-2026 02-06-2026 08-06-2026 22-06-2026 16-07-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) FAQs

toggle

What is the current price of GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ)?

The current price of GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) is $0.5532.


toggle

GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) absolute price change since previous trading day?

The absolute price change of GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) since the previous trading day is $0.0397.


toggle

GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) percentage price change since previous trading day?

The percentage price change of GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) since the previous trading day is 7.7313%.


toggle

What is the most recent average sentiment score for GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ)?

The most recent average sentiment score for GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) is 87 out of 100.


toggle

What is the most recent average sentiment for GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ)?

The most recent sentiment for GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ) is .


SEC-8K** Filing Available For GALMED PHARMACEUTICALS LTD (GLMD:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.